Aytu BioPharma vs Tonix Pharmaceuticals
AYTU and TNXP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AYTU and TNXP compare
Tonix Pharmaceuticals is the larger company, worth 2.7 times as much as Aytu BioPharma ($51.6M against $19.3M).
Tonix Pharmaceuticals grew revenue faster over the last twelve months (318% versus −13.3% for Aytu BioPharma).
Aytu BioPharma keeps more of each dollar of sales as profit, with a net margin of −24.8% compared with −420% at Tonix Pharmaceuticals.
Tonix Pharmaceuticals scores higher on the StockData Score (10 against 9 for Aytu BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AYTU | TNXP |
|---|---|---|
| Size and price | ||
| Market cap | $19.3M | $51.6M |
| Share price | $1.78 | $3.01 |
| Change, 1 year | −13.6% | −83.0% |
| Change, 5 years | −95.6% | −100.0% |
| Beta (5Y) | 1.05 | 2.01 |
| Employees | 76 | 142 |
| StockData Score | ||
| Total score | 9 | 10 (better) |
| Valuation score | 3 | 3 |
| Growth score | 0 | 2 (better) |
| Performance score | 3 (better) | 0 |
| Health score | 3 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.3× (better) | 1.2× |
| P/B | 0.5× | 0.3× (better) |
| P/FCF | 5.9× | – |
| FCF yield | 16.8% (better) | −329% |
| Fair value | $8.51 | $18.27 |
| Margin of safety | 79.1% | 83.5% (better) |
| Growth | ||
| Revenue growth (TTM) | −13.3% | 318% (better) |
| Revenue growth, 5Y average | −2.6% | – |
| Profitability | ||
| Gross margin | 64.0% | 89.3% (better) |
| Operating margin | −14.4% (better) | −436% |
| Net margin | −24.8% (better) | −420% |
| FCF margin | 5.6% (better) | −395% |
| Return on equity | −52.6% (better) | −84.1% |
| Return on invested capital | −63.5% (better) | −388% |
| Financial health | ||
| Debt / equity | 0.31 (better) | 0.00 |
| Interest coverage | −4.4× | – |
| Current ratio | 1.13 | 4.57 (better) |
| Altman Z-score | −4.10 (better) | −6.62 |
| Piotroski F-score | 3 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −288% |
| Shareholder yield | 0.00% (better) | −288% |
| Ownership | ||
| Held by institutions | 45.3% | 54.6% |
| Held by insiders | 15.1% | 0.27% |
| Insider net buying, 12 months | – | $479K |
| Short interest, % of float | 3.3% | 19.4% |
Go deeper
- AYTU stock overview
- AYTU income statement
- AYTU valuation and score
- TNXP stock overview
- TNXP income statement
- TNXP valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.